E N D
The global small molecule API market is projected to grow from $164.59 billion in 2024 to $286.03 billion by 2032, with a CAGR of 7.2%. North America leads the market with a 37.86% share in 2023. Key segments include: Type: Branded and generic APIs Indication: Oncology, diabetes, cardiovascular diseases Manufacturing: Captive and merchant production Major market drivers: Rising chronic disease prevalence driving drug demand Strong R&D pipeline with 58% being small molecules Growing regulatory approvals (55 drug molecules approved by FDA in 2023, 34 being small molecules) Expansion of manufacturing capacity by key players Notable developments: Cambrex completed phase 1 of its $30 million API facility expansion in North Carolina (September 2022) Axplora received cGMP approval for expanded HPAPI manufacturing (October 2023) MilliporeSigma opened a $65 million HPAPI facility focused on cancer treatments (June 2022) Leading companies include Lonza, EuroAPI, and Pfizer Inc., with operations across North America, Europe, and Asia Pacific. Footnotes Fortune Business Insights - Small Molecule API Market Size, Share & Growth Report, 2032 https://www.fortunebusinessinsights.com/small-molecule-api-market-107457